Literature DB >> 7508904

Abundant but inactive-state gp140proto-trk is expressed in neuroblastomas of patients with good prognosis.

H Iwata1, T Ito, T Mutoh, Y Ishiguro, H Xiao, M Hamaguchi.   

Abstract

Steady-state levels of gp140proto-trk in cell lines and tumor tissues of neuroblastoma were examined by immunoblotting with anti-gp140proto-trk. The level of gp140proto-trk varied but showed good correlations with the stage of the tumor and the age of the patients at the time of diagnosis. Moreover, patients with higher expression of gp140proto-trk clearly had a far better survival rate than those with lower expression, suggesting that suppression of gp140proto-trk strongly correlates with the malignant conversion of the tumor. However, we found that neither autophosphorylation of gp140proto-trk nor tyrosine phosphorylation of cellular proteins was elevated in tumors of the higher expression group. These results suggest that gp140proto-trk does not actively participate in the process of transformation or the suppression of malignant conversion. Rather, the higher level of gp140proto-trk may reflect the greater level of differentiation of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508904      PMCID: PMC5919340          DOI: 10.1111/j.1349-7006.1994.tb02883.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

1.  Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.

Authors:  C Ellis; M Moran; F McCormick; T Pawson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

2.  The trk proto-oncogene product: a signal transducing receptor for nerve growth factor.

Authors:  D R Kaplan; B L Hempstead; D Martin-Zanca; M V Chao; L F Parada
Journal:  Science       Date:  1991-04-26       Impact factor: 47.728

3.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

4.  Association of p60src with Triton X-100-resistant cellular structure correlates with morphological transformation.

Authors:  M Hamaguchi; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

6.  Neuroblastoma, its natural history and prognosis: a study of 487 cases.

Authors:  L M Wilson; G J Draper
Journal:  Br Med J       Date:  1974-08-03

7.  Transposition and amplification of oncogene-related sequences in human neuroblastomas.

Authors:  N E Kohl; N Kanda; R R Schreck; G Bruns; S A Latt; F Gilbert; F W Alt
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

Authors:  A Nakagawara; M Arima-Nakagawara; N J Scavarda; C G Azar; A B Cantor; G M Brodeur
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

9.  Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines.

Authors:  N Sidell; A Altman; M R Haussler; R C Seeger
Journal:  Exp Cell Res       Date:  1983-10       Impact factor: 3.905

10.  p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system.

Authors:  M Hamaguchi; N Matsuyoshi; Y Ohnishi; B Gotoh; M Takeichi; Y Nagai
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

View more
  2 in total

1.  Ganglioside GM1 binds to the Trk protein and regulates receptor function.

Authors:  T Mutoh; A Tokuda; T Miyadai; M Hamaguchi; N Fujiki
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

2.  Insulin-like growth factor II in the pathogenesis of human neuroblastoma.

Authors:  K A Sullivan; V P Castle; S M Hanash; E L Feldman
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.